Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.95 USD | +1.56% | +4.84% | -2.01% |
May. 14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
May. 13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 55.24M | Sales 2025 * | 64.37M | Capitalization | 33.88M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -18M | EV / Sales 2024 * | 0.61 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.53 x |
P/E ratio 2024 * |
-1.65
x | P/E ratio 2025 * |
-2
x | Employees | 177 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.53% |
Latest transcript on Exagen Inc.
1 day | +1.56% | ||
1 week | +4.84% | ||
1 month | +43.38% | ||
3 months | -3.47% | ||
6 months | +1.04% | ||
Current year | -2.01% |
Managers | Title | Age | Since |
---|---|---|---|
John Aballi
CEO | Chief Executive Officer | 39 | 22-10-16 |
Kamal Adawi
DFI | Director of Finance/CFO | 45 | 17-05-31 |
Ming-Chou Lee
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Robertson
BRD | Director/Board Member | 61 | 19-07-29 |
Paul Kim
BRD | Director/Board Member | 56 | 23-07-23 |
Wendy Johnson
BRD | Director/Board Member | 72 | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.95 | +1.56% | 25,030 |
24-05-30 | 1.92 | +0.52% | 45,363 |
24-05-29 | 1.91 | -1.29% | 13,820 |
24-05-28 | 1.935 | +4.03% | 16,721 |
24-05-24 | 1.86 | -7.00% | 37,900 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.01% | 33.88M | |
+25.52% | 88.99B | |
-24.52% | 74.82B | |
-2.75% | 25.03B | |
+4.31% | 17.88B | |
-14.25% | 16.43B | |
+2.97% | 15.77B | |
+79.20% | 13.21B | |
+70.11% | 13.08B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- XGN Stock